Loading...
•
Dec 31, 2024
OmniAb Q4 2024 Earnings Report
OmniAb reported strong fourth-quarter growth in revenue driven by higher license and milestone income, despite reporting a net loss.
Key Takeaways
OmniAb delivered $10.8 million in Q4 2024 revenue, more than doubling year-over-year, primarily due to higher license and milestone revenue. The company continues to expand its partnerships and clinical-stage programs while maintaining steady operating expenses.
Total revenue reached $10.8 million, up from $4.8 million in Q4 2023.
License and milestone revenue rose to $8.7 million from $1.7 million year-over-year.
Net loss decreased to $13.1 million compared to $14.1 million in Q4 2023.
Signed two new license agreements in the quarter with Incyte Corporation and Photinia Biosciences.
OmniAb
OmniAb
OmniAb Revenue by Segment
Revenue by Segment
License and milestone Revenue
CapyFin.comService Revenue
CapyFin.comRoyalty Revenue
CapyFin.com Forward Guidance
OmniAb expects continued growth in 2025, with anticipated revenue between $20 million and $25 million, reduced cash use, and further expansion of its clinical pipeline and partnerships.
Positive Outlook
- 2025 revenue guidance between $20 million and $25 million.
- Anticipated lower cash use compared to 2024.
- Ongoing expansion in the number of active partners and clinical programs.
- Focus on scaling business operations and launching new platform enhancements.
- Strong potential for additional milestone achievements and royalties.
Challenges Ahead
- Ongoing net losses expected while investments in R&D continue.
- Potential fluctuations in royalty revenue due to partner sales performance.
- Competitive pressures in the biotech technology platform space.
- Dependence on partner execution and development timelines.
- Macroeconomic uncertainties could impact business operations and funding.